key: cord-0841612-xnkn38i9
authors: van der Ploeg, Kattria; Kirosingh, Adam S.; Mori, Diego A.M.; Chakraborty, Saborni; Hu, Zicheng; Sievers, Benjamin L.; Jacobson, Karen B.; Bonilla, Hector; Parsonnet, Julie; Andrews, Jason R.; Press, Kathleen D.; Ty, Maureen C.; Ruiz-Betancourt, Daniel R.; Parte, Lauren de la; Tan, Gene S.; Blish, Catherine A.; Takahashi, Saki; Rodriguez-Barraquer, Isabel; Greenhouse, Bryan; Singh, Upinder; Wang, Taia T.; Jagannathan, Prasanna
title: TNFα-producing CD4+ T cells dominate the SARS-CoV-2-specific T cell response in COVID-19 outpatients and are associated with durable antibodies
date: 2022-05-03
journal: Cell Rep Med
DOI: 10.1016/j.xcrm.2022.100640
sha: a49cf1719c2e267abf1320e15f94d5a14b896a2b
doc_id: 841612
cord_uid: xnkn38i9

SARS-CoV-2-specific CD4+ T cells are likely important in immunity against COVID-19, but our understanding of CD4+ longitudinal dynamics following infection, and specific features that correlate with the maintenance of neutralizing antibodies, remains limited. Here, we characterize SARS-CoV-2-specific CD4+ T cells in a longitudinal cohort of 109 COVID-19 outpatients enrolled during acute infection. The quality of the SARS-CoV-2-specific CD4+ response shifts from cells producing IFNγ to TNFα from five days to four months post-enrollment, with IFNγ-IL21-TNFα+ CD4+ T cells the predominant population detected at later timepoints. Greater percentages of IFNγ-IL21-TNFα+ CD4+ T cells on day 28 correlate with SARS-CoV-2 neutralizing antibodies measured seven months post-infection (⍴=0.4, P=0.01). mRNA vaccination following SARS-CoV-2 infection boosts both IFNγ and TNFα producing, spike protein-specific CD4+ T cells. These data suggest that SARS-CoV-2-specific, TNFα-producing CD4+ T cells may play an important role in antibody maintenance following COVID-19.

Besides Th1 cells, virus-specific CD4 + T cells also differentiate into T follicular helper (Tfh) cells to instruct B cells, by producing IL21 for instance, to develop long-term humoral immunity. 23, 24, 33, 34 Circulating Tfh cells (cTfh) have been identified following acute SARS-CoV-2 infection 10, 12, 25, 27, [35] [36] [37] [38] [39] , although their formation may be delayed 35 

PBMCs were obtained from 109 COVID-19 outpatients enrolled in a Phase 2 trial of Peginterferon Lambda-1a (Lambda) at enrollment (D0), and 5, 14, 28, and 120 days postenrollment. The median age of participants was 37 years, 59% percent were male, and the median duration of symptoms prior to enrollment was five days (IQR 4-7 days, Supplemental Table 1 ). Following enrollment, participants completed a daily at home symptom questionnaire, with a median duration until symptom resolution of eight days following enrollment. 40 As previously described, two participant groups were identified based on symptom trajectory analysis, with one cluster (n=7/109 (6.4%)) characterized by greater symptom severity and/or later peak severity, especially chest pain/pressure, fatigue, and myalgias, and the other cluster characterized by more mild symptoms. 41 We first investigated the magnitude and quality of SARS-CoV-2-specific T cell responses on day 28 (D28) post-enrollment using intracellular cytokine staining (ICS). PBMCs were stimulated with two PepTivator Ⓡ SARS-CoV-2 peptide pools: membrane glycoprotein and nucleocapsid phosphoprotein, pooled together (MN), or spike (S) protein, and assessed for intracellular production of IFNγ, TNFɑ, IL10, and IL21. Antigen-specific CD4 + T cells were J o u r n a l P r e -p r o o f 6 identified by first gating on non-naïve CD4 + T cells (excluding CCR7 + CD45RA + CD4 + T cells, Figure 1A and Supplemental Figure 1A ). As we detected no antigen-specific CD4 + T cell production of IL10 (Supplemental Figure 1C) , downstream analyses focused on IFNγ, TNFɑ, and IL21. We found that SARS-CoV-2-specific CD4 + T cells consist of four distinct cytokineproducing populations: TNFɑ alone (IFNγ -IL21 -TNFɑ + ), IFNγ alone (IFNγ + IL21 -TNFɑ -), IL21

alone (IFNγ -IL21 + TNFɑ -) or both IFNγ and TNFɑ (IFNγ + IL21 -TNFɑ + ), with the highest percentages of cells being IFNγ -IL21 -TNFɑ + ( Figure 1B and Supplemental Figure 1C ). In separate experiments, we found that the majority of IFNγ -IL21 -TNFɑ + -and IFNγ + IL21 -TNFɑ + CD4 + T cells also co-produce IL2 (Supplemental Figure 2 ). Percentages of MN-specific IFNγ -IL21 -TNFɑ + , IFNγ + IL21 -TNFɑand IFNγ + IL21 -TNFɑ + cells were slightly greater compared to S protein-specific cells ( Figure 1B) . When considering the quality of the SARS-CoV-2 specific CD4 + T cell response (e.g., the proportion of antigen-specific cells making specific cytokines, alone or in combination), >50% of the MN-and S-specific CD4 + T cell response was comprised of IFNγ -IL21 -TNFɑ + cells ( Figure 1B ). CD4 + T cells producing TNFɑ alone were significantly higher in males compared to females, older participants (>35 years of age), and those experiencing greater symptom severity and/or later peak severity as previously defined 41 (Supplemental Figure 3 ), consistent with published reports. 7,14 SARS-CoV-2-specific CD8 + T cells were overall low and heterogeneous with a few high responders (Supplemental Figure 4A , 4B), and less abundant than SARS-CoV-2-specific CD4 + T cells in this ICS assay, consistent with other reports. 13, 25 No significant differences in cytokine-producing SARS-CoV-2-specific CD4 + or CD8 + T cells were observed between Peginterferon Lambda and placebo treatment arms (Supplemental Figure 5A , 5B). Together, these data suggest that SARS-CoV-specific IFNγ -IL21 -TNFɑ + CD4 + T cells are the dominant population detected 28 days post-enrollment in this 7 outpatient cohort, and their magnitude is influenced by participant gender, age, and disease severity.

As an alternate approach to ICS, we also performed an activation induced marker (AIM) assay to assess SARS-CoV-2-specific CD4 + T cells via upregulation of CD137 and OX40

(Supplemental Figure 1B) . 2, 7, 27, 42 In contrast to responses characterized by ICS, we observed similar percentages of AIM + CD4 + T cells following MN-and S-protein stimulation ( Figure 1D ).

In addition, similar percentages of AIM + cells were found between CD4 + and CD8 + T cells following MN stimulation (Supplemental Figure 1C and Supplemental Figure Figure   6A ). This changing quality of CD4 + T cells was observed following both MN and S protein stimulation ( Figure 2B ). Similar results were observed when analyzing T cell responses considering days since symptom onset (rather than days since enrollment) (Supplemental Figure   6B -D), as well as when analyzing samples from the Lambda and placebo arm separately (Supplemental Figure 5D , 5F). Among non-naïve cytokine-producing CD8 + T cells, IFNγ + IL21 -TNFɑcells were the predominant population up to D28, followed by IFNγ + IL21 -TNFɑ + cells at four months post-enrollment. These findings were driven by a few high responders, which was particularly observed after MN stimulation (Supplemental Figure 4E , 4F).

To further characterize CD4 + IFNγ + and TNFɑ + cells, we examined CCR7 cell surface receptor expression to better understand their differentiation status (e.g., central memory versus effector memory). SARS-CoV-2-specific IFNγ -IL21 -TNFɑ + CD4 + T cells had significantly higher CCR7 mean fluorescence intensity compared to IFNγ + IL21 -TNFɑor IFNγ + IL21 -TNFɑ + cells ( Figure 2C , 2D). This suggests that CD4 + T cells producing TNFɑ alone were more central memory-like, while the IFNγ-producing populations were more effector memory-like. Together, these data suggest a shift in the magnitude and quality of the SARS-CoV-2-specific CD4 + T cell response over time with a switch from an IFNγ-producing effector memory-like response at early timepoints to a TNFα-producing, central memory-like response at later timepoints.

J o u r n a l P r e -p r o o f 9

We next profiled other CD4 + T cell populations longitudinally, including SARS-CoV-2specific AIM + (CD137 + OX40 + ) CD4 + , cTfh (PD-1 + CXCR5 + CD4 + ), activated cTfh (ICOS + ), and SARS-CoV-2-specific AIM + cTfh cells (PD-1 + CXCR5 + OX40 + CD137 + ) ( Figure 3B and Supplemental Figure 1B for gating). We observed similar percentages of SARS-CoV-2-specific AIM + CD4 + T cells between D5 and D28, although both MN and S protein-specific AIM + CD4 + declined between D28 and D120 ( Figure 3A ). In general, cTfh percentage remained similar over time with the exception of a greater percentage of cTfh cells on D5 compared to D28 ( Figure   3C ). Activated cTfh percentage declined after D14 ( Figure 3D ). SARS-CoV-2-specific AIM + Tfh cells were detectable up to four months after enrollment and magnitudes remained largely unchanged over time ( Figure 3E ).

Subsequently, we assessed the relationship between production of cytokines and expression of activation markers, specifically investigating correlations between 1) SARS-CoV-2-specific cytokine-producing CD4 + T cell percentages measured in ICS experiments and 2)

Percentages of SARS-CoV-2-specific AIM + CD4 + and the three different cTfh populations measured in the AIM assays, since it is unclear how these T cell populations relate to each other.

All IFNγ-and TNFɑ-producing CD4 + T cell populations positively and significantly correlated with AIM + CD4 + , AIM + cTfh, and ICOS + cTfh. In contrast, IFNγ -IL21 + TNFɑ -CD4 + T cells did not correlate with circulating percentages of cTfh cells ( Figure 3F , 3G). Together, these data suggest that SARS-CoV-2-specific TNFɑ and IFNγ-producing CD4 + T cell populations highly correlated with SARS-CoV-2-specific AIM + CD4 + T cell and cTfh cell populations, but that, in our assay, IL21 production did not correlate with either AIM + or cTfh cell populations.

J o u r n a l P r e -p r o o f

Neutralizing antibodies are thought to be the primary adaptive effector function that mediate protection from COVID-19 re-infection. [20] [21] [22] CD4 + T helper responses are important in germinal center immune reactions and affinity maturation, and antigen-specific cTfh were recently described to be a correlate of the peak antibody response following SARS-CoV-2 vaccination. 9 We thus explored whether specific CD4 + T cell features following natural infection correlated with the antibody response measured at timepoints in the future, including S protein binding IgG and neutralizing antibody titers (Supplemental Figure 5D ). 43 We first evaluated whether SARS-CoV-2-specific CD4 + T cell responses measured early following infection (D5) correlated with the peak antibody response, measured on D28 postenrollment. 43 Figure 5G , 5H). In linear models adjusted for treatment arm, gender and age, associations between MN protein-specific Log10 IFNγ -IL21 -TNFɑ + -producing CD4 + T cells and antibody responses on D210 remained significant (Table 1) . Similarly, associations between ICOS + cTfh on D28 and antibody responses on D210 remained significant after multivariate adjustment (Table 1) . We observed similar positive correlations when analyzing associations between month four (D120) T cell responses and D210 antibody responses, particularly after MN stimulation, but these associations were not significant, likely given the small sample size at month four (Supplemental Figure 7C , 7D). Taken together, these findings show that SARS-CoV-2-specific IFNγ -IL21 -TNFɑ + CD4 + T cells and activated, ICOS + cTfh on D28 correlate with SARS-CoV-2-specific antibody responses measured more than seven months post-infection.

Given the robust associations between SARS-CoV-2-specific IFNγ -IL21 -TNFɑ + CD4 + T cells and ICOS + cTfh, and durable neutralizing antibody titers, we next sought to identify early, infection-induced determinants of this response. We performed whole blood RNA sequencing and plasma proteomics by Olink on D0 and D5 post-enrollment 45 , and correlated these measurements with the D28 SARS-CoV-2-specific CD4 + T cell response ( Figure 5A ). Several Table 2 ) and ICOS + cTfh cells ( Figure 5C and Supplemental Table 3 ). Several of these proteins were associated with both cellular populations, including monocyte-chemotactic protein 3 (MCP-3, also known as CCL7), eukaryotic translation initiation factor 4 gamma 1 (EIF4G1), DNA fragmentation factor subunit alpha (DFFA) and C-X-C motif chemokine ligand 1 (CXCL1) ( Figure 5B , 5D). MCP-3 is a cytokine induced by IFNγ, and acts as a chemoattractant for activated leukocytes including CCR2 + monocytes. 46, 47 Although elevated levels of MCP3 have previously been implicated in the pathogenesis of severe COVID-19 45, 48, 49 , our data suggest that it may also be a useful early biomarker for the initiation of a robust, long-lived adaptive cellular immune response.

COVID-19 vaccines elicit robust humoral and CD4 + T cell responses among participants who had not been previously exposed to SARS-CoV-2. [50] [51] [52] [53] However, little has been reported to date on the CD4 + T cell response following mRNA vaccination among individuals who have experienced SARS-COV-2 infection. 8, 9 We evaluated the SARS-CoV-2-specific CD4 + T cell response in study participants who received two doses of a COVID-19 mRNA vaccine either prior to the month seven (n=2) or month ten (M10) (n=18) follow-up visits, and compared these changes to unvaccinated participants. As expected, we found that the magnitude of S proteinspecific, but not MN protein-specific, IFNγ + IL21 -TNFɑ --and IFNγ + IL21 -TNFɑ + -producing CD4 + T cells was increased in the post-vaccination samples only ( Figure 6A and Supplemental Figure 8A ). The M10/D28 ratio of S protein-specific IFNγ + IL21 -TNFɑcells was 3.3-fold higher, and IFNγ + IL21 -TNFɑ + cells 4.9-fold higher, comparing vaccinated to unvaccinated participants.

In contrast, we observed a more modest, 1.4-fold increase in the M10/D28 ratio of S protein-J o u r n a l P r e -p r o o f 13 specific IFNγ -IL21 -TNFɑ + cells ( Figure 6B ). These differences did not appear to be driven by time since second dose (Supplemental Figure 8B ). Additionally, vaccinated individuals had a 4.3-fold higher M10/D28 ratio of S protein-specific AIM + cTfh cells compared to unvaccinated participants ( Figure 6C ), without boosting of AIM + CD4 + T cells or activated cTfh cells (Supplemental Figure 8C , 8D). Together, these findings show that mRNA vaccination boosted S protein-specific CD4 + T cells that produced IFNγ, with or without TNFɑ, along with AIM + cTfh cells.

In Polyfunctional CD4 + Th1 cells producing IFNγ and TNFα (along with IL2) have been thought to be important in response to some viral infections, including HIV and influenza. 32, 54, 55 This polyfunctional Th1 cytokine profile has been observed among convalescent mild and severe COVID-19 patient in several studies 2, 6, 13, 25, 27, [29] [30] [31] 39 , although the importance of this versus other cytokine-producing populations of circulating SARS-CoV-2-specific CD4 + T cells remains unclear. However, many of these studies were cross-sectional in nature, with significant heterogeneity observed. 11, 25, 27, 28, 31 In the present study, we detected a substantial proportion of CD4 + T cells producing both IFNγ and TNFα (along with IL2) that peaked in percentage early in convalescence. In contrast, at later timepoints, TNFα-producing cells, without IFNγ, were the predominant population detected in our ICS assay. This finding is particularly relevant given the development of clinical assays designed to detect SARS-CoV-2-specific T cell responses via measurement of IFNγ release 56 , and suggest that assays measuring SARS-CoV-2-specific TNFα production, and/or IL2 production 57 , could be considered as a tool to define previous exposure to SARS-CoV-2.

In addition to measuring SARS-CoV-2-specific T cells by ICS, we also utilized an AIM assay employing markers for both CD4 + T cells and cTfh cells, and similar with published reports 7,15 , detected SARS-CoV-2-specific AIM + CD4 + T cells up to ten months post-enrollment.

Moreover, we observed that cytokine-producing CD4 + T cell populations -in particular, TNFɑ its association with early disease progression. 45, 48, 49 No correlation was observed between IL21producing CD4 + T cells and cTfh cells. This was unexpected given that IL21 is thought to be a canonical cTfh cytokine. 23, 24, 33, 34 Furthermore, we were unable to detect any antigen-specific IL10 production. One possible explanation for these findings is that our ICS assay was not optimized to detect SARS-CoV-2-specific IL21 or IL10 production, although we and others have successfully used a similar approach to detect these CD4 + T cell cytokines in other settings. 59 Alternatively, it is possible that cTfh are not representative of germinal center Tfh in this setting, or that these cytokines may not be induced in the SARS-CoV-2-specific CD4 + T cell compartment following infection, although this will require further validation in other cohorts and settings.

Although several studies have reported correlations between SARS-CoV-2-specific CD4 + T cell responses and SARS-CoV-2-specific antibody titers measured at either the peak of response or at concurrent timepoints 7, 13, 27, 30, 35, 60 , there is limited data correlating infectioninduced CD4 + T cell responses with antibodies measured prospectively. Although SARS-CoV-2specific, polyfunctional IFNγ and TNFα co-producing CD4 + T cells at D5 correlated with the neutralizing antibody response at D28 by Spearman correlation, this finding was not significant after multiple comparison correction. In contrast, we observed that TNFα-single positive cells measured on D28, rather than polyfunctional, IFNγ and TNFα co-producing cells, were most strongly correlated with neutralizing antibodies measured seven months post-enrollment. We Given our study design, we were positioned to compare CD4 + T cell responses among previously infected study participants who did and did not receive two doses of a COVID-19

mRNA vaccine during follow-up. We found that mRNA vaccination particularly boosts S protein-specific CD4 + T cells that produce IFNγ, with or without TNFɑ, along with AIM + cTfh cells. There was only modest boosting of TNFɑ single positive cells, and no boosting of MN protein-specific cells. These findings are consistent with a recent systems analysis of immune responses following the BNT162b2 mRNA vaccine. 61 In that study, Arunachalam and colleagues found that vaccination resulted in robust expansion of IFNγ-producing CD4 + T cells, although they observed no significant correlation between levels of IFNγ producing CD4 + T cells and the neutralizing antibody response measured prospectively. In another study by Painter and colleagues, the percentage of antigen-specific cTfh cells prior to the second dose of mRNA vaccination correlated with post-second dose neutralizing antibody titers. In contrast, pre-second dose antigen-specific Th1 cells were less well correlated, suggesting distinct associations between Th populations and vaccine-elicited immune responses. 9 Together, these data suggest 

This study had some limitations. Half of the study participants in this trial received an investigational Type III IFN at the time of infection. However, in our study, this agent neither shortened the duration of viral shedding nor symptoms 40 , nor did we observe any significant impact on either innate 45 or adaptive immune responses between arms (Supplemental Figure 5 ), allowing us to utilize data from both arms to improve statistical power. Furthermore, stratified analyses, and multivariate models adjusted for treatment arm as a covariate, confirmed pooled results, though this may differ in alternative study populations. We would have liked to have assessed for correlations with protection against reinfection; however, only one participant had evidence of reinfection during follow-up. Future larger cohorts, and/or case/control designs, will be required to address this question. Next, analysis of T cell cytokine production was only performed by an ICS assay. Although SARS-CoV-2 specific CD8 + T cells were low and less abundant than CD4 + T cells in the ICS assay, consistent with published reports 13, 25 , similar percentages of antigen-specific CD8 + and CD4 + T cells were detected by an AIM assay, raising the question whether ICS adequately detects the cytokines being produced. ICS using alternative cytokines, longer stimulation periods, and/or alternative methods for cytokine detection (e.g. Table S2 and Table S3 . 

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Prasanna Jagannathan (prasj@stanford.edu).

This study did not generate new unique reagents.  Other underlying data for this paper will be shared by the lead contact upon request without restriction.

27

The samples used were from 109 participants enrolled in a Phase 2, single-blind, randomized placebo-controlled trial evaluating the efficacy of Peginterferon Lambda-1a in SARS-CoV-2 infected outpatients. 40 The trial was registered at ClinicalTrials.gov Table 1 . Participants were invited to return for long-term follow-up visits at month four, month seven and month ten post-enrollment for a symptom survey, clinical assessment, assessment of vaccination status, and peripheral blood biobanking. Overall, 20 participants received 2 doses of COVID-19 mRNA vaccine before month seven (n=2) or month ten (n=18) follow-up visits (median 30 days since second dose at time of sampling, range 6-78). We also collected blood and serum samples from healthy volunteers, without known SARS-CoV-2 exposure, aged 22-35 to serve as our non-J o u r n a l P r e -p r o o f 28 exposed controls. All participants gave written informed consent. The study protocol used was approved by the Institutional Review Board of Stanford University.

The generation of vesicular stomatitis virus (VSV) pseudotyped with the S of SARS-CoV-2 used in the neutralization assays to infect Vero cells (ATCC, CCL-81) were made as described previously. 43 Vero cells are derived from an adult African green monkey. The sex of the cells is unknown because it is not specified by ATCC. Cells were grown and maintained in 1× Dulbecco's modified Eagle medium (Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (FBS).

Blood was collected from study participants in two BD Vacutainer® CPT™ Mononuclear Cell Preparation Tubes, which provide a fully-closed system for separation of mononuclear cells from whole blood. The tubes were centrifuged at 1800 g for 20 minutes, following centrifugation plasma was separated into a 15 mL centrifuge tube, centrifuged again at 1200 g for 10 minutes, then aliquot and stored at -80ºC. The PBMC layer was transferred to a 50 mL centrifuge tube, washed twice with Gibco DPBS and centrifuged at 300 g for 10 minutes. 

ELISA and neutralizing assay were performed as described in detail previously. 43 In In the neutralizing assay the percent infection was calculated based on the 'virus only' controls and then the percent inhibition was determined by subtracting the percent infection from 100. A non-linear curve and the half-maximal neutralization titer (NT50) were generated using Prism 9 (GraphPad).

Using Kallisto (v0.46.2) 64 the transcript-level count data and transcript per million (TPM) data were calculated. Human cDNA index was produced using Kallisto on Ensembl (v96)

transcriptomes. All gene ontology terms that are the child term of immune system process were identified (GO:0002376). Highly redundant gene ontology terms by grouping terms with >80% overlap of genes were removed, followed by manually selecting the representative terms within each group. The single-sample enrichment score of each gene ontology term was calculated for each RNA-seq sample by using the fgsea R package. 65 Gene ontology term enrichment scores were treated as variables, similar to individual protein markers, in downstream analysis. We tested associations between plasma proteins measured by Olink, whole blood transcriptomics, and CD4 + T cell responses using regression models and the lm function in R, immune response, as described in an early publication. 45 The P value of the regression coefficient of the measurement term is used to determine the significance of association between T cell response and the immune measurements. The False Discovery Rate (FDR) method is used to adjust for the multiple hypothesis testings when assessing the association between T cell response and the immune measures (plasma proteins and immune pathways).

Two-sided p-values were calculated for all test statistics and P<0.05 was considered significant.

Clinical trial: https://clinicaltrials.gov/ct2/show/NCT04331899

Supplemental Information PDF Supplemental Table 2 . Correlations between plasma proteins, transcriptomic signatures and IFNγ -IL21 -TNFɑ + SARS-CoV-2-specific T cells. Related to Figure 5 .

Supplemental Table 3 . Correlations between plasma proteins, transcriptomic signatures and ICOS + cTfh cells. Related to Figure 5 . Pathways associated with IFNγ-IL21-TNFα+ nnCD4

Proteins associated with IFNγ-IL21-TNFα+ nnCD4

Pathways associated with ICOS+ Tfh Proteins associated with ICOS+ Tfh 

T cell responses in patients with COVID-19

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Adaptive immunity to SARS-CoV-2 and COVID-19

Serial SARS-CoV-2 Receptor-Binding Domain Antibody Responses in Patients Receiving Dialysis

Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection

Persistent cellular immunity to SARS-CoV-2 infection

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern

Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination

Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19

Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients

Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19

Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection

Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells

SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent patients for 10 months with successful development of stem cell-like memory T cells

Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms

A strategic approach to COVID-19 vaccine R&D

The COVID-19 vaccine development landscape

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate

A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

T Follicular Helper Cell Biology: A Decade of Discovery and Diseases

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19

Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome

T-cell quality in memory and protection: implications for vaccine design

IL-21 and IL-6 Are Critical for Different Aspects of B Cell Immunity and Redundantly Induce Optimal Follicular Helper CD4 T Cell (Tfh) Differentiation

Interleukin-21 Is a Critical Cytokine for the Generation of Virus-Specific Long-Lived Plasma Cells

SARS-CoV-2-specific circulating T follicular helper cells correlate with neutralizing antibodies and increase during early convalescence

Peripheral CD4+ T cell subsets and antibody response in COVID-19 convalescent individuals

Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19

Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4+ T Cells in COVID-19

SARS-CoV-2-Specific T Cells Exhibit Phenotypic Features of Helper Function, Lack of Terminal Differentiation, and High Proliferation Potential

Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial

Inflammatory but not respiratory symptoms are associated with ongoing upper airway viral shedding in outpatients with uncomplicated COVID-19

Comparative analysis of activation induced marker (AIM) assays for sensitive identification of antigen-specific CD4 T cells

Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity

Anti-spike antibody response to natural SARS-CoV-2 infection in the general population

Early immune responses have long-term associations with clinical, virologic, and immunologic outcomes in patients with COVID-19

Differential induction of monocyte chemotactic protein-3 in mononuclear leukocytes and fibroblasts by interferon-α / β and interferon-γ reveals MCP-3 heterogeneity

Human monocyte chemotactic proteins-2 and -3: structural and functional comparison with MCP-1

Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages

Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19

Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63

HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells

COMPASS identifies T-cell subsets correlated with clinical outcomes

Interferon-γ Release Assay for Accurate Detection of Severe Acute Respiratory Syndrome Coronavirus 2 T-Cell Response

Rapid measurement of SARS-CoV-2 spike T cells in whole blood from vaccinated and naturally infected individuals

Single-cell RNAseq and computational analysis using temporal mixture modelling resolves Th1/Tfh fate bifurcation in malaria

IFNγ/IL-10 Coproducing Cells Dominate the CD4 Response to Malaria in Highly Exposed Children

Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals

Systems vaccinology of the BNT162b2 mRNA vaccine in humans

T cell responses to SARS-CoV-2 spike cross-recognize Omicron

SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron

Near-optimal probabilistic RNA-seq quantification

Fast gene set enrichment analysis

SPICE: Exploration and analysis of post-cytometric complex multivariate datasets